AstraZeneca Pharma India has announced its intention to sell a 64-acre property in Bengaluru for approximately INR 3,400 crores. This sale could mark a significant financial move for the pharmaceutical company.

AstraZeneca has secured government approval to introduce Acalabrutinib tablets into the Indian market, providing additional treatment alternatives for individuals battling specific blood cancers like Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). This move will broaden therapeutic options in India.

AstraZeneca's Calquence, a leukemia treatment drug, has been given the green light by India's CDSCO for import, paving the way for its use in battling the disease.